Organisation paid for research Program year 2025 Source: CMS Open Payments

Future Care Solution LLC

Neither a doctor nor a teaching hospital

Research payments

$5,810,141

678 payments

Through program year 2025, Future Care Solution LLC is reported as receiving $5,810,141 in research payments, across 678 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$1,373,494	317
2024	Research	$381,843	63
2023	Research	$25,800	5
2022	Research	$373,854	76
2021	Research	$1,578,651	108
2020	Research	$1,594,658	81
2019	Research	$481,842	28

Breakdown

Who paid Research payments · program years 2019–2025

ACADIA Pharmaceuticals Inc $1,892,120 382 payments
GlaxoSmithKline, LLC. $1,793,585 69 payments
AbbVie, Inc. $1,228,170 45 payments
Sanofi US Services Inc. $412,226 24 payments
Eli Lilly and Company $387,751 8 payments
Esperion Therapeutics, Inc. $93,567 149 payments
Janssen Research & Development, LLC $2,722 1 payment

Studies the money was for Research payments · program years 2019–2025

Acp-204-006 $784,288 220 payments
M16-100 $691,802 22 payments
A 24-Week, Phase 3, Multicentre, Randomised, Double-Blind, Efficacy An $691,644 22 payments
A 52-Week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy An $647,583 34 payments
Acp-204-008 $535,223 134 payments
A Multi-Centre Long-Term Extension Study to Assess the Safety and Effi $454,359 13 payments
Acp-103-047 $416,447 23 payments
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimers Disease $360,589 3 payments
Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men (TRAVERSE) Study $277,384 11 payments
A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men $217,700 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.